The boom in cell and gene therapies is clear to see. The number of firms in this space has increased 309% from 218 in 2010 to 892 in 2018, according to the Alliance for Regenerative Medicine, and the number of clinical trials has grown from 301 to 995 in that same time. Attendance at ARM’s Cell and Gene Meeting on the Mesa also has grown, from 350 attendees in 2010 to almost 1,200 in 2018.
Other Cell And Gene Meeting Coverage
For additional coverage from ARM's annual conference, see these stories:
Cell And Gene Therapies Test New Waters In Pricing And Reimbursement
This year's cell and gene therapy studies include 323 Phase I, 579 Phase II and 93 Phase III trials. Those studies and ongoing preclinical research are supported by a massive influx of capital. ARM reports that investment in the sector has grown 564% from $1.5bn in 2010 to $10.3bn year-to-date in 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?